Aesthetics Biomedical® Raises Multi-Million-Dollar Funding Round to Expand Vivace® and SoME® Skincare Products

Phoenix-based biomedical innovator holds numerous patents and trademarks in the rapidly growing aesthetics industry
“Decathlon’s investment allows us to deliver these ground-breaking aesthetic treatments and products to providers and consumers and continue to build the most innovative solutions in the marketplace.”
Aesthetics Biomedical®, a fast-growing innovator in skincare and aesthetic therapies, has reached an agreement with Decathlon Capital Partners on a multi-million-dollar funding round to fuel the company’s continued growth.

The investment will specifically fund Aesthetics Biomedical’s Vivace® Microneedle RF and SoME® Skincare products. Vivace® is a fractional microneedle device that stimulates collagen production and reduces the effects of skin aging. SoME® Skincare is an anti-aging cosmetic product that, at a physician’s discretion, uses a patient’s own platelet rich plasma (PRP) to deliver a topical, daily, at-home personalized skin rejuvenation system.

Aesthetics Biomedical® was founded in 2016 and has grown rapidly as its innovative aesthetics products, devices and services have been adopted across the nation by the aesthetic industry. The company holds numerous patents, pending patents and trademarks in skincare, collagen regeneration and other ground-breaking therapies.

MaryAnn Guerra, Aesthetics Biomedical’s founder and CEO

“Aesthetics Biomedical® has advanced the world of personalized aesthetics and minimally-invasive skincare procedures that turn back the clock on aging skin,” said MaryAnn Guerra, Aesthetics Biomedical’s founder and CEO. “Decathlon’s investment allows us to deliver these ground-breaking aesthetic treatments and products to providers and consumers and continue to build the most innovative solutions in the marketplace.”

Decathlon Capital’s investment will be repaid through the company’s future revenue, which allows Aesthetics Biomedical® founders and owners to maintain full control of the company’s future.

“Decathlon is proud to invest in a company that has shown itself to be a model of innovation in the aesthetics industry,” said John Borchers, Decathlon Capital Partners’ managing partner. “The product vision, intellectual property and technical expertise at Aesthetics Biomedical® will continue to fuel the company’s long-term growth in an exciting and expanding industry.”

The global aesthetics market was estimated at approximately $52.5 billion in 2018, according to Grand View Research, and is expected to grow at a compounded annual rate of 8.9 percent through 2026. That growth will be led by non-invasive and minimally invasive procedures — which Aesthetics Biomedical® specializes in — and powered by the population growth in the 30-65 year-old demographic.

About Aesthetics Biomedical®
Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical’s innovation center is a leader in breakthrough technologies and combination therapies for its clients, provider network and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. Learn more at

About Decathlon Capital Partners
Decathlon Capital Partners provides growth capital for companies seeking alternatives to traditional equity investment. Through the use of highly customized revenue-based financing solutions, Decathlon provides long-term growth capital without the dilution, loss of control and operational overhead that often comes with equity-based funding. With offices in Palo Alto and Park City, Decathlon is the largest revenue-based funding investor in the U.S. and is active across a wide range of sectors. Learn more at

Posted in AZBio News.